Deep vein thrombosis screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 13: Line 13:
*Thrombosis occurring in unusual vascular beds such as portal, hepatic, mesenteric, or cerebral veins
*Thrombosis occurring in unusual vascular beds such as portal, hepatic, mesenteric, or cerebral veins
*History of [[warfarin]]-induced skin necrosis.
*History of [[warfarin]]-induced skin necrosis.
==Who should not screened?==


===Probability scoring===
===Probability scoring===

Revision as of 20:27, 30 August 2011

Deep Vein Thrombosis Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Deep vein thrombosis from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Approach

Assessment of Clinical Probability and Risk Scores

Assessment of Probability of Subsequent VTE and Risk Scores

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Venography

CT

MRI

Other Imaging Findings

Treatment

Treatment Approach

Medical Therapy

IVC Filter

Invasive Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Special Scenario

Upper extremity DVT

Recurrence

Pregnancy

Trials

Landmark Trials

Case Studies

Case #1

Deep vein thrombosis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Deep vein thrombosis screening

CDC on Deep vein thrombosis screening

Deep vein thrombosis screening in the news

Blogs on Deep vein thrombosis screening

Directions to Hospitals Treating Deep vein thrombosis

Risk calculators and risk factors for Deep vein thrombosis screening

Overview:Value of screening

In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening, the following reason explains

  • The strongest risk factor for VTE recurrence is the prior VTE event itself.
  • After discontinuation of warfarin in VTE patients, especially where the cause was unknown, there are still at high risk of recurrence. irrespective of the presence of inherited thrombophilia.
  • Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations.

Who should be screened?

Patients having any of the following, should be screened for inherited Thrombophilia

  • Initial thrombosis occurring at age<50, without an immediately identified risk factor
  • Positive family history of thromboembolism at age<50
  • Recurrent venous thrombosis
  • Thrombosis occurring in unusual vascular beds such as portal, hepatic, mesenteric, or cerebral veins
  • History of warfarin-induced skin necrosis.

Who should not screened?

Probability scoring

In 2006, Scarvelis and Wells overviewed a set of clinical prediction rules for DVT,[1] on the heels of a widely adopted set of clinical criteria for pulmonary embolism.[2][3]

Wells score or criteria

(Possible score -2 to 9)

1) Active cancer (treatment within last 6 months or palliative) -- 1 point
2) Calf swelling >3 cm compared to other calf (measured 10 cm below tibial tuberosity) -- 1 point
3) Collateral superficial veins (non-varicose) -- 1 point
4) Pitting edema (confined to symptomatic leg) -- 1 point
5) Swelling of entire leg - 1 point
6) Localized pain along distribution of deep venous system -- 1 point
7) Paralysis, paresis, or recent cast immobilization of lower extremities -- 1 point
8) Recently bedridden > 3 days, or major surgery requiring regional or general anesthetic in past 12 weeks -- 1 point
9) Previously documented DVT -- 1 point
10) Alternative diagnosis at least as likely -- Subtract 2 points

Interpretation

Score of 2 or higher - deep vein thrombosis is likely. Consider imaging the leg veins.
Score of less than 2 - deep vein thrombosis is unlikely. Consider blood test such as d-dimer test to further rule out deep vein thrombosis.

Cases have been reported when the well score was zero [4].

References

  1. Scarvelis D, Wells P (2006). "Diagnosis and treatment of deep-vein thrombosis". CMAJ. 175 (9): 1087–92. PMID 17060659. Free Full Text.
  2. Neff MJ. ACEP releases clinical policy on evaluation and management of pulmonary embolism. American Family Physician. 2003; 68(4):759-?. Available at: http://www.aafp.org/afp/20030815/practice.html. Accessed on: December 8, 2006.
  3. Wells P, Anderson D, Rodger M, Ginsberg J, Kearon C, Gent M, Turpie A, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J (2000). "Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer". Thromb Haemost. 83 (3): 416–20. PMID 10744147.
  4. Pai RP, Kangath RV, Brown TA (2011). "Saddle pulmonary thromboembolism with zero Wells' score". Conn Med. 75 (2): 89–91. PMID 21476378.